CN114053317A - Composition for wound healing - Google Patents

Composition for wound healing Download PDF

Info

Publication number
CN114053317A
CN114053317A CN202110797610.9A CN202110797610A CN114053317A CN 114053317 A CN114053317 A CN 114053317A CN 202110797610 A CN202110797610 A CN 202110797610A CN 114053317 A CN114053317 A CN 114053317A
Authority
CN
China
Prior art keywords
composition
less
weight
present disclosure
ginseng fruit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110797610.9A
Other languages
Chinese (zh)
Inventor
金炫秀
李垠秀
黄晶娥
金东泫
朴录贤
洪勇德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Publication of CN114053317A publication Critical patent/CN114053317A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat

Abstract

The present invention relates to a wound healing composition comprising ginseng berry extract as an active ingredient, which has the advantage of having excellent keratinocyte regeneration effect and wound healing effect by comprising ginseng berry extract as an active ingredient according to the present disclosure.

Description

Composition for wound healing
Technical Field
Disclosed is a composition for wound healing, which contains a ginseng berry extract as an active ingredient.
Background
The skin is the first line of defense of the body that serves to protect the body's defense membranes, and is an important organ with multiple physiological functions. Skin wounds, fire, abrasions and other injuries caused by trauma accomplish healing and functional recovery through natural processes, preventing deterioration of the condition and infection through treatment. For wound healing, wound protection and cell regeneration inducing treatments are required. In korean laid-open patent No. 10-1995-7003309, a method of promoting topical wound treatment in warm-blooded animals is disclosed, which comprises the step of administering a therapeutically effective amount of a composition comprising peptone digest complexed with ionic transition metal to the wound, however, there is a need to develop a composition for wound healing through crude drug components harmless to the organism.
[ Prior art documents ]
[ patent document ]
(patent document 1) Korea publication No. 10-1995-
Disclosure of Invention
Technical problem to be solved
The present disclosure is made to solve the above problems, and an object of the present disclosure is to provide a composition having a keratinocyte regeneration effect and a wound healing effect.
Technical scheme
In order to achieve the above objects of the present disclosure, the present disclosure provides a composition for wound healing comprising ginseng berry extract as an active ingredient.
In one aspect, the present disclosure provides a use of a ginseng berry extract for preparing a composition for wound healing.
Effects of the invention
According to the present disclosure, since the ginseng berry extract is contained as an active ingredient, there is an advantage in that the keratinocyte regeneration effect and the wound healing effect are excellent.
Drawings
FIG. 1 is a graph showing the results of analyzing the components of an extract according to an example;
fig. 2 to 4 are graphs showing evaluation results of the skin cell damage improvement efficacy according to an example.
Detailed Description
As for terms used in the present specification, general terms widely used at present are selected as much as possible in consideration of their functions in the present disclosure, however, they may be different according to intentions of those skilled in the art, cases, or the emergence of new technology, etc. In addition, terms arbitrarily selected by the applicant may be used in a special case, and the meanings thereof will be described in detail in the corresponding detailed description section. Therefore, the terms used in the present disclosure should not be defined by simple names of the terms but by meanings the terms have and contents throughout the present disclosure.
Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Terms that are generally understood should be interpreted as having the same meaning as commonly understood in the context of the relevant art and should not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
Numerical ranges include the numbers defined in the disclosure. All maximum numerical limitations in this specification are expressly written with a lower numerical limitation, including all lower numerical limitations. All minimum numerical limitations given throughout this specification are to be understood as meaning higher numerical limitations, including all higher numerical limitations. All numerical limitations in this specification are to be understood as if they were expressly written to include narrower numerical limitations than those expressly written to include all numerical limitations that are more completely within the broader numerical range.
The present disclosure is specifically described below with reference to examples and drawings. However, it should be understood that the present invention is not limited by the following examples and drawings.
In one aspect, the present disclosure provides a composition for wound healing comprising ginseng berry extract as an active ingredient.
The "ginseng" may be Korean ginseng, Panax ginseng.
The "ginseng fruit" refers to a fruit produced during the growth of ginseng. Specifically, it may mean that fruits bearing about one week in about 7 middle ten days as 3 to 5-year-old ginseng, more specifically 4-year-old ginseng. The ginseng fruit used in the present disclosure is not limited to the starting method, and may be cultivated or purchased commercially for use.
The "extract" includes all components and substances obtained from natural substances regardless of the extraction method, the extraction solvent, or the form of the extract. The extraction method may include a process of processing or treating by other methods after extracting components or substances obtained from natural substances. In particular, the processing or treatment by other methods may be further fermentation or enzymatic treatment of the extract. Therefore, the extract in the present disclosure is a broad concept including a fermented product, a concentrated product, and a dried product, and particularly, the extract in the present disclosure may be a fermented product.
The "ginseng fruit extract" includes all components and substances obtained from ginseng fruit regardless of the extraction method, the extraction solvent or the form of the extract. The extraction method may include a process of treatment using heat, acid (acid), base (base), enzyme, etc., or may include a process of processing or treating by other methods after extracting components, substances obtained from ginseng fruit. Specifically, the processing or treatment by other methods may be further fermentation or enzyme treatment of the ginseng fruit extract. Therefore, the ginseng fruit extract in the present disclosure is a broad concept including a fermented product, a concentrated product, and a dried product, and particularly, the extract in the present disclosure may be a fermented product. In addition, the extraction method may include a step of concentrating the ginseng fruit extract under reduced pressure. The concentration under reduced pressure may be specifically carried out at 35 to 50 ℃, but is not limited thereto. When the concentration is performed under reduced pressure at a temperature within the range, the ginseng fruit extract of the present invention is excellent in synergistic effect of various components. The concentration under reduced pressure may be specifically 600mmHg or more, 620mmHg or more, 640mmHg or more, 660mmHg or more, 680mmHg or more, 700mmHg or more, 720mmHg or more, 740mmHg or more; 760mmHg or less, 740mmHg or less, 720mmHg or less, 700mmHg or less, 680mmHg or less, 660mmHg or less, 650mmHg or less, 640mmHg or less, 620mmHg or less, and 600mmHg or less.
As an extraction method for obtaining the "ginseng fruit extract", heating extraction, cold-soaking extraction, reflux-cooling extraction, ultrasonic extraction, or the like can be used, but the extraction method is not limited as long as it is obvious to those skilled in the art. As an extraction solvent used for obtaining "ginseng fruit extract", ginseng fruit extract of the present specification may use C of ginseng fruit1-C6The alcohol extract is, specifically, ethanol or the like, however, it is not limited as long as it is an extraction solvent apparent to those skilled in the art. The "ginseng fruit extract" can be an extract of fresh ginseng fruit or an extract of dried ginseng fruit.
In one aspect, the "ginseng fruit extract" may be prepared as follows: 1) harvesting fresh ginseng (Panax ginseng C.A. Meyer) seeds; 2) removal or not removal of seeds; 3) sun-drying or hot-air drying pulp and pericarp (including seeds when the seeds are not removed) of herba Herminii to obtain herba Herminii dried material, 4) adding water or organic solvent (especially ethanol) into the obtained herba Herminii dried material, extracting at room temperature, filtering, and concentrating under reduced pressure at 40-45 deg.C and 600-700 mmHg.
In other aspects, the "ginseng fruit extract" may be prepared as follows: 1) harvesting fresh ginseng (Panax ginseng C.A. Meyer) seeds; 2) removal or not removal of seeds; 3) juicing pulp and pericarp of herba Herminii (including seeds when not removed).
In one aspect, the "ginseng fruit extract" may include Protopanaxatriol (PT) ginsenoside Re, Rg1, Rg2 and Protopanaxadiol (PD) ginsenoside Rb1, Rb2, Rb3, Rc, Rd.
According to an embodiment of the present disclosure, the ratio (PD/PT) of protopanoxadiol-type ginsenosides relative to protopanaxatriol-type ginsenosides in the ginseng fruit extract may be 0.1 to 0.4. Within the range, the synergistic effect of the various components in the ginseng fruit extract of the present invention is more excellent. More specifically, the PD/PT may be 0.1 or more, 0.15 or more, 0.2 or more, 0.216 or more, 0.25 or more, 0.3 or more, 0.35 or more, or 0.4 or more; less than 0.726, 0.7 or less, 0.65 or less, 0.6 or less, 0.55 or less, 0.5 or less, 0.45 or less, 0.4 or less, 0.35 or less, 0.3 or less, 0.25 or less.
However, the ginseng fruit extract in the present disclosure is not only the ginsenoside component but also a composition of a plurality of substances including inorganic substances and anthocyanins, and thus the effect exerted by the composition of the present disclosure is a synergistic effect produced by the combination of the plurality of substances, and is not produced by a single ginsenoside or a combination of ginsenosides (for example, saponins) alone.
The wound (wind) refers to the damage trace of organism, including body wound and dermal wound. According to an embodiment of the present disclosure, the wound may be a skin wound.
The "wound healing" is the regeneration, differentiation, proliferation of cells while maintaining lost continuity again, and according to an embodiment of the present disclosure, the composition is used for cell regeneration. In terms of the wound healing mechanism, when a wound occurs in an organism, blood fills the wound site due to the natural healing action of the organism, the particle reduction of platelets and contact factors (hageman factors) are activated to start the wound healing process. The coagulation of blood serves as a temporary defense, protecting exposed wound tissue, and providing a foundation for cell movement during the healing process (Lee et al, Skin barrier, Ryo Moon Gak, 2004).
The subsequent wound healing process is roughly divided into four steps, an inflammation stage, a re-epithelialization stage, a proliferation stage and a maturation stage. During the inflammatory phase, immune cells appear at the wound site, which cells are moving from the blood vessel to the wound site. Subsequently, growth factors and signaling substances that induce the formation of granular tissue are secreted. The inflammatory phase generally proceeds relatively short in the absence of major infection (Care KRGf. Advances in wind Care. Seoul: Korea Medical Book Publisher, 2002). The inflammatory phase is an essential step in the wound healing process.
The proliferative phase occurs similarly to the re-epithelialization phase and shows the characteristic of granular tissue formation at the wound site (Kubo et al, J Artif Organs,6(1):64-70,2003). Particulate tissue, together with fibroblasts (fibroblasts) and inflammatory cells (inflammatory cells), is composed of a combination of extracellular matrix components such as immature collagen (immature collagen), fibronectin (fibronectin), and hyaluronic acid (hyaluronic acid), and it is important for wound healing that the particulate tissue rapidly fills up a wound portion and has a tissue structure.
The surface of the peeled wound is covered with a layer of keratinocytes (keratinocytes) to produce a new epidermis, which is reconstituted. The keratinocytes are the primary cells responsible for the re-epithelialization phase step in wound healing, and in the "cell regeneration" of the present disclosure, the cells may be keratinocytes.
At the end of re-epithelialization of the wound, a series of processes of wound area reduction is performed by a combination of tissue augmentation and reconstruction. Then, during the maturation phase, the coagulated cells and capillaries of the healing tissue gradually disappear, and scars are produced when the tissue is excessively formed or not normally decomposed. This is the normal wound healing process. The wound healing includes the meaning of promoting wound healing based on the natural healing action of organisms by the active ingredient of the present disclosure.
In the wound healing process, it is important not only to rapidly treat the wound but also to treat the wound without side effects or scars, and thus, it is more important that tissue cells are uniformly filled by inhibiting inflammation and regulating the expression of growth factors.
According to an embodiment of the present disclosure, the ginseng fruit extract is used in an amount of 13mg/kg to 200mg/kg per 1 day. More specifically, the daily usage amount may be more than 12.5mg/kg, 13mg/kg or more, 15mg/kg or more, 20mg/kg or more, 25mg/kg or more, 30mg/kg or more, 35mg/kg or more, 40mg/kg or more, 45mg/kg or more, 50mg/kg or more, 55mg/kg or more, 60mg/kg or more, 65mg/kg or more, 70mg/kg or more, 75mg/kg or more, 80mg/kg or more, 85mg/kg or more, 90mg/kg or more, 95mg/kg or more, 100mg/kg or more, 105mg/kg or more, 110mg/kg or more, 115mg/kg or more, 120mg/kg or more, 125mg/kg or more, 130mg/kg or more, 135mg/kg or more, 140mg/kg or more, 145mg/kg or more, 150mg/kg or more, 155mg/kg or more, 160mg/kg or more, 165mg/kg or more, 170mg/kg or more, 175mg/kg or more, 180mg/kg or more, 185mg/kg or more, 190mg/kg or more; 200mg/kg or less, 195mg/kg or less, 190mg/kg or less, 185mg/kg or less, 180mg/kg or less, 175mg/kg or less, 170mg/kg or less, 165mg/kg or less, 160mg/kg or less, 155mg/kg or less, 150mg/kg or less, 145mg/kg or less, 140mg/kg or less, 135mg/kg or less, 130mg/kg or less, 125mg/kg or less, 120mg/kg or less, 115mg/kg or less, 110mg/kg or less, 105mg/kg or less, 100mg/kg or less, 95mg/kg or less, 90mg/kg or less, 85mg/kg or less, 80mg/kg or less, 75mg/kg or less, 70mg/kg or less, 65mg/kg or less, 60mg/kg or less, or more, or less, or a combination thereof, 55mg/kg or less, 50mg/kg or less, 45mg/kg or less, 40mg/kg or less, 35mg/kg or less, 30mg/kg or less, 25mg/kg or less, but not limited thereto. The use can also be divided for use from one to a plurality of times in 1 day. For example, 1 day 2 to 24, 3 days 1 to 2, 1 week 1 to 6, 2 weeks 1 to 10, 3 weeks 1 to 15, 4 weeks 1 to 3, or 1 year 1 to 12 times can be used.
The term "use" refers to a case where the composition is provided to a subject by any suitable method, and means including administration, coating, absorption, ingestion, and the like. In this case, the subject refers to all animals such as humans, monkeys, dogs, sheep, pigs, or mice to which the composition can be administered.
According to an embodiment of the present disclosure, the content of the ginseng fruit extract may vary according to a dosage form, use, number of use, and route of use. In particular, in the case where the composition of the present disclosure is formulated into a non-oral dosage form such as an injection, or an oral dosage form such as a food, a pill, or a syrup, the content of the active ingredient of the present disclosure may vary depending on the intestinal absorption rate, the digestion rate, and the like. However, when the composition of the present disclosure is prepared as a skin external preparation to be topically applied, 780mg to 12000mg may be used for a subject having a body weight of 60kg in consideration of the 1-day usage amount. Assuming that the coating amount per 1 day is 100g, the content of the effective ingredient of the present disclosure may contain a content of 0.78 wt% to 12 wt% with respect to the total weight of the composition.
More specifically, the content may be more than 0.75% by weight, 0.78% by weight or more, 0.9% by weight or more, 1.0% by weight or more, 1.5% by weight or more, 2.0% by weight or more, 2.5% by weight or more, 3.0% by weight or more, 3.5% by weight or more, 4.0% by weight or more, 4.5% by weight or more, 5.0% by weight or more, 5.5% by weight or more, 6.0% by weight or more, 6.5% by weight or more, 7.0% by weight or more, 7.5% by weight or more, 8.0% by weight or more, 8.5% by weight or more, 9.0% by weight or more, 9.5% by weight or more, 10.0% by weight or more, 10.5% by weight or more, 11.0% by weight or more, 11.4% by weight or more; 12.0% by weight or less, 11.7% by weight or less, 11.4% by weight or less, 11.0% by weight or less, 10.5% by weight or less, 10.0% by weight or less, 9.5% by weight or less, 9.0% by weight or less, 8.5% by weight or less, 8.0% by weight or less, 7.5% by weight or less, 7.0% by weight or less, 6.5% by weight or less, 6.0% by weight or less, 5.5% by weight or less, 5.0% by weight or less, 4.5% by weight or less, 4.0% by weight or less, 3.5% by weight or less, 3.0% by weight or less, 2.5% by weight or less, 2.0% by weight or less, 1.5% by weight or less, however, not limited thereto.
According to an embodiment of the invention, the composition is a pharmaceutical composition for wound improvement or therapy. In addition, according to an embodiment of the present disclosure, the composition is a health food composition for wound improvement. In addition, according to an embodiment of the present disclosure, the composition is a cosmetic composition for wound improvement.
By "improving" is meant a parameter that is related to the status of the treatment, such as all actions that at least reduce the symptomatic condition. The term "treatment" refers to all actions whereby the symptoms of a disease are ameliorated or improved by the use of the composition.
According to an embodiment of the present disclosure, the composition is a pharmaceutical composition. In this case, a pharmaceutically acceptable carrier may be included. The carrier is used in the sense of comprising an excipient, diluent or adjuvant. The carrier may be selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginic acid, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, polyvinylpyrrolidone, water, physiological saline, a buffer such as PBS, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil, for example. The composition may also include fillers, anti-coagulants, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, or combinations thereof.
The pharmaceutical composition is administered in a pharmaceutically effective amount. The "pharmaceutically effective amount" refers to an amount sufficient for preventing or treating a disease at a reasonable benefit/risk ratio that can be used, and the effective capacity criterion may be determined according to factors including the kind of disease of a patient, the severity of the disease, the activity of a drug, the sensitivity to a drug, the administration time, the administration route and discharge ratio, the treatment time, the drug used at the same time, and other pharmaceutically known factors.
The pharmaceutical composition may be formulated as an oral dosage form (e.g., powder, tablet, capsule, syrup, pill, or granule) or a non-oral dosage form (e.g., injection).
The pharmaceutical composition can be formulated into a systemic dosage form or a topical dosage form, and in particular, can be applied to the skin as an external preparation for the skin. The skin external preparation can be in the form of liquid, ointment, cream, lotion, spray, patch, gel or aerosol. When used as an external preparation for skin, the composition may further contain an auxiliary agent generally used in the field of skin science, such as a fatty substance, an organic solvent, a dissolving agent, a concentrating agent, a gelling agent, an emollient, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or nonionic emulsifier, a filler, a metal ion-blocking agent, a chelating agent, a preservative, a vitamin, a blocking agent, a wetting agent, an essential oil, a dye, a pigment, a hydrophilic or lipophilic activator, a lipid vesicle, or any other component generally used in external preparations for skin. In addition, the ingredients may be introduced in amounts generally used in the field of skin science. The skin external agent composition may further include an agent for increasing percutaneous absorption, such as dimethyl sulfoxide, dimethylacetamide, dimethylformamide, a surfactant, azone, ethanol, acetone, propylene glycol or polyethylene glycol.
The pharmaceutical compositions may be administered as individual therapeutic agents or together with other therapeutic agents, may be administered sequentially or simultaneously with existing therapeutic agents, and may be administered in a single or multiple dose. It is important to consider all of the factors and to administer in an amount that will give the maximum effect in the least amount possible without side effects, which can be readily determined by one skilled in the art. In addition, the pharmaceutical compositions may be used alone or in combination with surgery, radiation therapy, hormonal therapy, chemotherapy and methods of using biological response modifiers.
According to an embodiment of the present disclosure, the composition is a health food composition. The health food composition may further include a physiologically acceptable carrier, and the kind of the carrier is not particularly limited as long as it is a carrier generally used in the art.
The health food composition may include food additives (food additives) such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), bactericides (bleaching powder and high-performance bleaching powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), etc.), colorants (tar pigments, etc.), coloring agents (sodium nitrite, sodium sulfite, etc.), bleaching agents (sodium sulfite), seasonings (MSG sodium glutamate, etc.), sweeteners (glycine, sodium cyclamate, saccharin, sodium, etc.), flavors (vanillin, lactones, etc.), bulking agents (alum, D-potassium hydrogen tartrate, etc.), fortifiers, emulsifiers, tackifiers (paste), coating agents, gum bases, foam inhibitors, solvents, modifiers, etc. The additives may be selected according to the kind of food, and may be used in an appropriate amount.
The health food composition may include additional ingredients that are commonly used in food compositions to enhance odor, mouthfeel, vision, and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, nicotinic acid (niacin), biotin (biotin), folic acid (folate), pantothenic acid (panthenonic acid), and the like may be included. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and the like; and lysine, tryptophan, desmosine and the like.
According to an embodiment of the present disclosure, the composition is a cosmetic composition. The cosmetic composition can be formulated into a dosage form by a usual method. In formulating The skin external preparations, reference may be made to The disclosure in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, and in formulating The Cosmetic compositions, reference may be made to The disclosure in The International Cosmetic Ingredient Dictionary published by The American Cosmetic perfume Association.
Specifically, the cosmetic composition can be prepared into a general emulsion type and a solubilizing type. For example, lotions formulated as soft lotions or nutritional lotions and the like; face lotions, body lotions, and the like; nourishing cream, moisturizing cream, eye cream, etc.; essence; cosmetic ointments; spraying; gelling; facial mask; sun cream; isolating frost; liquid type, solid type, or spray type, etc.; pulverizing; makeup remover such as makeup removing cream, makeup removing oil, etc.; or cleaning agents for cleansing foams, soap, bath lotion, etc. In addition, the external preparation for skin may be formulated as an ointment, a patch, a gel, a cream, or a spray.
In each formulation of the cosmetic composition, other components may be appropriately mixed in addition to the ginseng fruit extract, depending on the type of formulation, the purpose of use, and the like, within a range that does not impair the purpose of the present disclosure.
The cosmetic composition may further contain an auxiliary agent commonly used in the cosmetic or dermatological field such as a fatty material, an organic solvent, a dissolving agent, a concentrating agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or nonionic emulsifier, a filler, a metal ion-blocking agent, a chelating agent, a preservative, a blocking agent, a wetting agent, an essential oil, a dye, a pigment, a hydrophilic or lipophilic activator, and any other ingredient commonly used in cosmetics, depending on the quality or function of the final product.
As another aspect, the present disclosure provides a use of a ginseng berry extract in preparing a composition for wound healing.
As another aspect, the present disclosure provides a method of wound healing, comprising: a step of using a composition containing a ginseng fruit extract as an active ingredient in an individual in need thereof.
As another aspect, the present disclosure provides a ginseng fruit extract for wound healing.
[ examples ] A method for producing a compound
Hereinafter, the present disclosure will be described in detail by examples. However, the following embodiments are merely examples shown to help fully understand the present disclosure, and the present disclosure is not limited to the following embodiments.
<Preparation example 1>Preparation of extracts of example 1 and comparative example 1
1. Preparation of the ginseng fruit extract of example 1
Fresh ginseng (Panax ginseng c.a.meyer) seeds (origin: korean nation) were harvested, and a ginseng fruit raw material containing seeds, juice, pulp, and pericarp of ginseng fruit was prepared without removing the seeds. Adding 6-10L 70% ethanol into 1kg of the prepared ginseng fruit raw material, extracting at normal temperature for 5-10 hours, filtering, and concentrating under reduced pressure at 50-70 ℃ to 600mmHg to obtain 3-5 g of ginseng fruit extract.
2. Preparation of Ginseng radix extract of comparative example 1
The ginseng root (origin: Korean) was used in place of the ginseng fruit, and 3-5 g of the ginseng root extract was prepared in the same manner as in example 1.
<Test example 1>Comparison of ginsenoside content
The ginseng fruit extract of example 1 and the ginseng root extract of comparative example 1 were dissolved in methanol, filtered using a 0.2um PTFE (Polytetrafluoroethylene) filter, and then measured using HPLC (high performance liquid chromatography). The ginsenoside content of the extract was analyzed, and the results are shown in the following Table 1 and FIG. 1 (unit: ug/g).
[ TABLE 1 ]
Ingredients (ug/g) Example 1 Comparative example 1
Ginsenoside Rb1 2921 2115
Ginsenoside Rb2 4016 1047
Ginsenoside Rb3 473 199
Ginsenoside Rc 2395 1225
Ginsenoside Rd 3022 349
Ginsenoside Rg1 4187 2557
Ginsenoside Re 54601 3186
Ginsenoside Rf 653 1054
Ginsenoside Ro 0 1635
Total amount of 72268 13367
As is clear from table 1 and fig. 1, it was confirmed that the total amount of ginsenosides in example 1 was significantly higher by about 5.4 times than in comparative example 1, and that when the ginsenosides were classified into Protopanaxatriol (PD) type ginsenosides (Rb1, Rb2, Rb3, Rc and Rd) and Protopanaxadiol (PT) type ginsenosides (Rg1, Re and Rf), they were 0.216 and 0.726, respectively, in the compositions, there was a significant difference between example 1 and comparative example 1.
<Test example 2>Evaluation of skin cell injury-improving efficacy 1
1. Evaluation method
HaCaT cells as a human keratinocyte strain (human keratinocyte) were plated at 2X 10 cells in 24-well cell culture dishes5cells/0.6 mL, 5% CO at 37 ℃2The culture was carried out under the conditions. After 24 hours, it was confirmed that the cells were sufficiently filled in the culture dish as a monolayer, and the cells were replaced with a cell culture medium containing 1% bovine fetal serum (FBS), and further cultured for 2 hours. After linear scratches were made on cells filled with a single layer using a scratch-only tool (SPL Scratccher, Cat No.201924), the cells were washed 2 times with a cell culture solution, and then 0.6mL of a cell culture solution (containing 1% fetal bovine serum) supplemented with extracts of ginseng fruit (GB) at concentrations of 12.5ppm, 25ppm, 50ppm, 100ppm, 200ppm, and 400ppm, respectively, was treated with each of the cells.
At this time, as a control group (non-treated group), 0.6mL of a cell culture solution (containing 1% fetal bovine serum) to which no extract of ginseng fruit was added was treated with the cells.
The treated HaCaT cells were then placed on a time-lapse microscope (JuLI stage image receiver, Nanoentek, Korea) and the scratch locations were stored as images (n-4 per group) at 1 hour intervals over a period of 48 hours.
Wound healing area (Wound healing area) (%) is calculated as a percentage of the area of cells filled over time relative to the initial scratch area, and the calculation of the area of cells filled is automatically calculated using the function of the software itself in conjunction with the time-lapse microscope. The results are shown in fig. 2 and 3.
2. Evaluation results
As can be seen from fig. 2 and 3, example 1 had an effect on keratinocyte regeneration in all concentration groups compared to the control group (non-treated group). This confirmed that the cell regeneration was excellent. Further, it was confirmed that the wound healing area was slightly decreased after 48 hours in the 50ppm treatment group compared to the 25ppm treatment group, and in addition, the wound healing area was sharply increased over the entire time in the 100ppm treatment group. Further, it was confirmed that the 400ppm treatment group had a decreased cell regeneration effect compared to the 200ppm treatment group.
<Test example 3>Evaluation of skin cell injury-improving efficacy 2
1. Evaluation method
The "Root" extract of comparative example 1 and the "ginseng fruit (GB)" extract of example 1 were each treated at a concentration of 25ppm or 50ppm under the same conditions as the evaluation method of the test example 2, and the skin cell damage-improving efficacy was evaluated. The results are shown in fig. 4.
2. Evaluation results
As can be seen from fig. 4, example 1 showed an excellent effect on cell regeneration in both concentration groups (25ppm and 50ppm) as compared with comparative example 1 and the control group (non-treated group).
Hereinafter, dosage form examples of the composition according to the present invention are explained, however, the pharmaceutical composition, the health food composition and the cosmetic composition may be applied in various dosage forms, which are only for concrete explanation and not for limiting the present invention.
[ dosage form example 1 ] preparation of ointment
Ointments were prepared by a usual method according to the components described in table 2 below.
[ TABLE 2 ]
Composition (I) Content (wt%)
The ginseng fruit extract of example 1 3.0
Cetostearyl alcohol 1.0
Self-emulsifying type monostearate 2.0
Stearic acid 1.0
Beeswax (Cera flava) 4.0
Squalane 7.0
Glyceryl monostearate 3.0
Sorbitan monostearate 1.0
Polysorbate 80 3.0
Glycerol 5.0
Propylene glycol 4.0
Perfume Proper amount of
Vaseline Residual amount of
[ dosage form example 2 ] preparation of drink preparation
According to the components described in the following table 3, a drink preparation was prepared by a usual method.
[ TABLE 3 ]
Composition (I) Content (wt%)
The ginseng fruit extract of example 1 0.2
Glucose 10
Citric acid 2
Purified water 188
[ dosage form example 3 ] preparation of Flexible astringent
According to the components described in the following table 4, a soft lotion was prepared by a usual method.
[ TABLE 4 ]
Composition (I) Content (wt%)
The ginseng fruit extract of example 1 3.0
Glycerol 5.0
1, 3-butanediol 3.0
Ethanol 5.0
Polyoxyethylene nonyl phenyl ether 0.5
Perfume Proper amount of
Preservative Proper amount of
Purified water Residual amount of
[ formulation example 4 ] preparation of astringent toner
Astringent lotions were prepared by a usual method with the components shown in the following Table 5.
[ TABLE 5 ]
Composition (I) Content (wt%)
The ginseng fruit extract of example 1 3.0
Glycerol 3.0
Citric acid 0.1
Ethanol 10.0
Polyoxyethylene oleyl ether 1.0
Sorbitol 2.0
Perfume Proper amount of
Preservative Proper amount of
Purified water Residual amount of
[ dosage form example 5 ] preparation of cream
The cream was prepared by a general method according to the components described in the following table 6.
[ TABLE 6 ]
Composition (I) Content (wt%)
The ginseng fruit extract of example 1 3.0
Glycerol 5.0
Stearic acid 8.0
Squalane 5.0
Self-emulsifying glyceryl monostearate 2.5
Polyoxyethylene sorbitan monostearate 1.5
Propylene glycol 4.0
Glycyrrhetinic acid stearyl alcohol ester 0.2
Vaseline 2.0
Antioxidant agent Proper amount of
Perfume Proper amount of
Preservative Proper amount of
Purified water Residual amount of
The present invention has been described with respect to the above-mentioned preferred embodiments, but various modifications or variations may be made without departing from the spirit and scope of the invention. Accordingly, the appended claims include such modifications or variations as fall within the true spirit of the invention.

Claims (10)

1. Use of a ginseng fruit extract for the preparation of a composition for wound healing.
2. The use of claim 1, wherein the wound is a skin wound.
3. The use of claim 1, wherein the composition is for cell regeneration.
4. Use according to claim 3, wherein the cells are keratinocytes.
5. The use according to claim 1, wherein the ginseng fruit extract is used in an amount of 13mg/kg to 200mg/kg per 1 day.
6. The use as claimed in claim 1, wherein the ginseng fruit extract is contained in an amount of 0.78 to 12 wt% based on the total weight of the composition.
7. The use according to claim 1, wherein the dry weight ratio of protopanaxadiol-type ginsenosides relative to protopanaxatriol-type ginsenosides in the ginseng fruit extract is 0.1 to 0.4.
8. The use of claim 1, wherein the composition is a pharmaceutical composition.
9. Use according to claim 1, wherein the composition is a health food composition.
10. Use according to claim 1, wherein the composition is a cosmetic composition.
CN202110797610.9A 2020-07-29 2021-07-14 Composition for wound healing Pending CN114053317A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2020-0094424 2020-07-29
KR1020200094424A KR20220014614A (en) 2020-07-29 2020-07-29 Composition for Recovering Wound

Publications (1)

Publication Number Publication Date
CN114053317A true CN114053317A (en) 2022-02-18

Family

ID=80233315

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110797610.9A Pending CN114053317A (en) 2020-07-29 2021-07-14 Composition for wound healing

Country Status (2)

Country Link
KR (1) KR20220014614A (en)
CN (1) CN114053317A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220014614A (en) * 2020-07-29 2022-02-07 (주)아모레퍼시픽 Composition for Recovering Wound

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080093266A (en) * 2007-04-16 2008-10-21 성인환 Concentrated liquid of ginseng fruit, manufacturing method thereof and health functional food
KR20090130801A (en) * 2008-06-16 2009-12-24 (주)아모레퍼시픽 Composition for applying to skin externally containing extract from seeds of ginseng
KR20110057895A (en) * 2009-11-25 2011-06-01 (주)아모레퍼시픽 Skin external composition for promoting the production of hyaluronic acid containing ginsenoside re and ginsenoside compound k
KR101051519B1 (en) * 2010-12-21 2011-07-22 한국인삼열매공사 주식회사 Method for manufacturing ginseng-berry extract
KR20180119771A (en) * 2017-04-26 2018-11-05 바이오스펙트럼 주식회사 A composition for treating skin wound comprising a stem cell culture medium treated with ginsenoside Rb3 as an active ingredient
KR20220014614A (en) * 2020-07-29 2022-02-07 (주)아모레퍼시픽 Composition for Recovering Wound

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080093266A (en) * 2007-04-16 2008-10-21 성인환 Concentrated liquid of ginseng fruit, manufacturing method thereof and health functional food
KR20090130801A (en) * 2008-06-16 2009-12-24 (주)아모레퍼시픽 Composition for applying to skin externally containing extract from seeds of ginseng
KR20110057895A (en) * 2009-11-25 2011-06-01 (주)아모레퍼시픽 Skin external composition for promoting the production of hyaluronic acid containing ginsenoside re and ginsenoside compound k
KR101051519B1 (en) * 2010-12-21 2011-07-22 한국인삼열매공사 주식회사 Method for manufacturing ginseng-berry extract
KR20180119771A (en) * 2017-04-26 2018-11-05 바이오스펙트럼 주식회사 A composition for treating skin wound comprising a stem cell culture medium treated with ginsenoside Rb3 as an active ingredient
KR20220014614A (en) * 2020-07-29 2022-02-07 (주)아모레퍼시픽 Composition for Recovering Wound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
宋肖洁，等: ""太空人参酵母"在化妆品中潜在应用研究", 日用化学工业, vol. 46, no. 12, pages 703 - 708 *

Also Published As

Publication number Publication date
KR20220014614A (en) 2022-02-07

Similar Documents

Publication Publication Date Title
US20080206175A1 (en) Composition for Skin Whitening and Wrinkle Improvement Comprising Vaccinium Uliginosum Extract and Method for Preparation Thereof
KR20180125612A (en) Avocado flesh and/or skin extract rich in polyphenols and cosmetic, dermatological and nutraceutical compositions comprising same
KR20110117376A (en) Composition containing red sword bean extract for anti-aging and whitening
KR101609340B1 (en) Composition comprising mixed herbal mixture extract for improving anti-aging or skin whitening
KR20150007975A (en) Composition for promoting hair growth and restoration
KR101315346B1 (en) Compositions for Improving Skin Conditions Using an Extract of Stichopus japonicus Red
CN114053317A (en) Composition for wound healing
KR20200080556A (en) Composition for preventing or treating skin disease comprising extract of Spiraea prunifolia simpliciflora
KR102577528B1 (en) Composition for improving skin
KR102194458B1 (en) Composition for Improving Wrinkle Using an Extract of Tripterygium regelii
KR20170025352A (en) Composition for improving skin
KR102611506B1 (en) Composition for improving skin condition comprising herb extracts mixture
KR102012170B1 (en) Composition comprising extracts of banana, cherry, and walnut for anti-skin aging
KR102262362B1 (en) Composition for improving skin conditions comprising an extract of oriental melon stem or cucumber stem
KR102509869B1 (en) Pharmaceutical composition for preventing or treating alopecia
KR20180041108A (en) Composition for improving skin
KR102229943B1 (en) Composition for Skin-lightening and Improving Wrinkle Using an Extract of Maerua edulis
KR102209664B1 (en) Composition for preventing or treating skin disease comprising extract of Euonymus alatus ciliatodentatus
KR102256821B1 (en) Composition for Improving Wrinkle Using an Extract of Filipendula palmata
JP2002080385A (en) Metal deposition inhibitor
KR20040011236A (en) Anti-allergic composition containing arctium lappa seed extract
KR20170025356A (en) Composition for improving skin
EP3818980A1 (en) Pharmaceutical composition comprising indirubin derivative as active ingredient
CN114053318A (en) Composition for controlling bacterial flora
KR20170025364A (en) Composition for improving skin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination